bluuebunny/crossref_metadata_2025 huggingface dataset:
Figure S1 from Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis
Authors: Lauer Ulrich M. , Schell Martina , Beil Julia , Berchtold Susanne , Koppenhöfer Ursula , Glatzle Jörg , Königsrainer Alfred , Möhle Robert , Nann Dominik , Fend Falko , Pfannenberg Christina , Bitzer Michael , Malek Nisar P.
Published: April 2023

Biological verification of calculated GL-ONC1 dosages.
Supplementary Tables from LIMS1 Promotes Pancreatic Cancer Cell Survival under Oxygen–Glucose Deprivation Conditions by Enhancing HIF1A Protein Translation
Authors: Huang Chongbiao , Li Yang , Li Zengxun , Xu Yang , Li Na , Ge Yi , Dong Jie , Chang Antao , Zhao Tiansuo , Wang Xiuchao , Wang Hongwei , Yang Shengyu , Xie Keping , Hao Jihui , Ren He
Published: April 2023

7 Supplementary Tables: Supplementary Table S1. Association between LIMS1 expression and clinicopathological features of patients with PDAC. Supplementary Table S2. Association between LIMS1 mRNA expression and clinicopathological features of PDAC patients from TCGA. Supplementary Table S3. Cox's proportional hazards model analysis of prognostic factors in patients with pancreatic ductal adenocarcinoma (PDAC) Supplementary Table S4. Association between LIMS1 expression and clinicopathological features of patients with esophageal cancer. Supplementary Table S5. Association between LIMS1 expression and clinicopathological features of patients with lung adenocarcinoma. Supplementary Table S6. Main antibodies and reagents. Supplementary Table S7. Primers and oligonucleotides sequences.
Supplementary Table S1 from Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary Breast Cancer Predicts Poor Clinical Outcome and Correlates with Suppressed Stat5 Signaling
Authors: Tran Thai H. , Utama Fransiscus E. , Sato Takahiro , Peck Amy R. , Langenheim John F. , Udhane Sameer S. , Sun Yunguang , Liu Chengbao , Girondo Melanie A. , Kovatich Albert J. , Hooke Jeffrey A. , Shriver Craig D. , Hu Hai , Palazzo Juan P. , Bibbo Marluce , Auer Paul W. , Flister Michael J. , Hyslop Terry , Mitchell Edith P. , Chervoneva Inna , Rui Hallgeir
Published: April 2023

List of Primers.
Supplementary Data from Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non–Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis
Authors: Datar Ila , Sanmamed Miguel F. , Wang Jun , Henick Brian S. , Choi Jungmin , Badri Ti , Dong Weilai , Mani Nikita , Toki Maria , Mejías Luis D. , Lozano Maria D. , Perez-Gracia Jose Luis , Velcheti Vamsidhar , Hellmann Matthew D. , Gainor Justin F. , McEachern Kristen , Jenkins David , Syrigos Konstantinos , Politi Katerina , Gettinger Scott , Rimm David L. , Herbst Roy S. , Melero Ignacio , Chen Lieping , Schalper Kurt A.
Published: April 2023

Supplementary Figures and Tables
Figure S7 from Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary Breast Cancer Predicts Poor Clinical Outcome and Correlates with Suppressed Stat5 Signaling
Authors: Tran Thai H. , Utama Fransiscus E. , Sato Takahiro , Peck Amy R. , Langenheim John F. , Udhane Sameer S. , Sun Yunguang , Liu Chengbao , Girondo Melanie A. , Kovatich Albert J. , Hooke Jeffrey A. , Shriver Craig D. , Hu Hai , Palazzo Juan P. , Bibbo Marluce , Auer Paul W. , Flister Michael J. , Hyslop Terry , Mitchell Edith P. , Chervoneva Inna , Rui Hallgeir
Published: April 2023

Supplementary Figure 7: Schematic representation of structure of wildtype Stat5a and Stat5b, dominant-negative Stat5 (DN-Stat5) and constitutively-active Stat5 (CA-Stat5) proteins.
Figure S9 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients
Authors: Hogan Daniel J. , Zhu Jay-Jiguang , Diago Oscar R. , Gammon Dawn , Haghighi Ali , Lu Guangrong , Das Asha , Gruber Harry E. , Jolly Douglas J. , Ostertag Derek
Published: April 2023

Figure S9
Figure S6 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients
Authors: Hogan Daniel J. , Zhu Jay-Jiguang , Diago Oscar R. , Gammon Dawn , Haghighi Ali , Lu Guangrong , Das Asha , Gruber Harry E. , Jolly Douglas J. , Ostertag Derek
Published: April 2023

Figure S6
Table S3 from Increased Synthesis of MCL-1 Protein Underlies Initial Survival of EGFR-Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug Target
Authors: Song Kyung-A , Hosono Yasuyuki , Turner Crystal , Jacob Sheeba , Lochmann Timothy L. , Murakami Yoshiko , Patel Neha U. , Ham Jungoh , Hu Bin , Powell Krista M. , Coon Colin M. , Windle Brad E. , Oya Yuko , Koblinski Jennifer E. , Harada Hisashi , Leverson Joel D. , Souers Andrew J. , Hata Aaron N. , Boikos Sosipatros , Yatabe Yasushi , Ebi Hiromichi , Faber Anthony C.
Published: April 2023

Sup. Table 3. Fold change of FBX7 from RNA-seq analysis.
Figure S1 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients
Authors: Hogan Daniel J. , Zhu Jay-Jiguang , Diago Oscar R. , Gammon Dawn , Haghighi Ali , Lu Guangrong , Das Asha , Gruber Harry E. , Jolly Douglas J. , Ostertag Derek
Published: April 2023

Figure S1
Supplmental Figures 1-3 from Combined BRAF and HSP90 Inhibition in Patients with Unresectable BRAFV600E-Mutant Melanoma
Authors: Eroglu Zeynep , Chen Y. Ann , Gibney Geoffrey T. , Weber Jeffrey S. , Kudchadkar Ragini R. , Khushalani Nikhil I. , Markowitz Joseph , Brohl Andrew S. , Tetteh Leticia F. , Ramadan Howida , Arnone Gina , Li Jiannong , Zhao Xiuhua , Sharma Ritin , Darville Lancia N.F. , Fang Bin , Smalley Inna , Messina Jane L. , Koomen John M. , Sondak Vernon K. , Smalley Keiran S.M.
Published: April 2023

Supplemental Figure 1. Clinical trial dose levels per cohort Supplemental Figure 2. SDS-PAGE Gel of Patients Tumor Homogenates for LC-MRM analysis. Proteins from patients tumor were fractionated with SDS-PAGE and visualized with Coomassie Brilliant Blue G-250 prior to gel excision. A control of WM-164 cell lysate was analyzed in parallel as a control. Supplemental Figure 3. Modified Ji design rules on dose escalation based on number of DLTs: *N: number of subjects treated at a given dose level. E: escalate to the next higher dose by enrolling 3 more subjects; S: stay at the same dose and enroll a cohort of 3 more subjects at that dose; DU: declare the current dose as unacceptable and unsafe, de-escalate to the lower dose, and enroll 3 more subjects at the lower dose; D: de-escalate to the lower dose, and enroll 3 more subjects at the lower dose; or C: study completed and dose is declared to be the MTD.
Supplementary Tables from Immunogenomic Analyses of Advanced Serous Ovarian Cancer Reveal Immune Score is a Strong Prognostic Factor and an Indicator of Chemosensitivity
Authors: Hao Dapeng , Liu Jie , Chen Meng , Li JingJing , Wang Li , Li Xiaobo , Zhao Qi , Di Li-jun
Published: April 2023

Supplementary Table 1 and Supplementary Table 2
Table S2 from Adjuvant Treatment for POLE Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues
Authors: Van Gool Inge C. , Rayner Emily , Osse Elisabeth M. , Nout Remi A. , Creutzberg Carien L. , Tomlinson Ian P.M. , Church David N. , Smit Vincent T.H.B.M. , de Wind Niels , Bosse Tjalling , Drost Mark
Published: April 2023

Oligonucleotide guide RNA sequences to introduce Pole proofreading domain mutations through CRISPR-Cas9
Supplemental Fig S6 from STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers
Authors: Moreira Dayson , Adamus Tomasz , Zhao Xingli , Su Yu-Lin , Zhang Zhuoran , White Seok Voon , Swiderski Piotr , Lu Xin , DePinho Ronald A. , Pal Sumanta K. , Kortylewski Marcin
Published: April 2023

Cytotoxic effect against human and mouse prostate cells in vitro
Figure S1 from Adjuvant Treatment for POLE Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues
Authors: Van Gool Inge C. , Rayner Emily , Osse Elisabeth M. , Nout Remi A. , Creutzberg Carien L. , Tomlinson Ian P.M. , Church David N. , Smit Vincent T.H.B.M. , de Wind Niels , Bosse Tjalling , Drost Mark
Published: April 2023

Fluorescent In Situ Hybridization of Pole on metaphase spreads of Pole-mutant cell line
Supplemental Fig S5 from STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers
Authors: Moreira Dayson , Adamus Tomasz , Zhao Xingli , Su Yu-Lin , Zhang Zhuoran , White Seok Voon , Swiderski Piotr , Lu Xin , DePinho Ronald A. , Pal Sumanta K. , Kortylewski Marcin
Published: April 2023

STAT3 silencing and PPS prostate cancer cell viability
Supplemental Fig S4 from STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers
Authors: Moreira Dayson , Adamus Tomasz , Zhao Xingli , Su Yu-Lin , Zhang Zhuoran , White Seok Voon , Swiderski Piotr , Lu Xin , DePinho Ronald A. , Pal Sumanta K. , Kortylewski Marcin
Published: April 2023

CpG-STAT3ASO conjugates colroccalize with RNaseH after internalization
Supplemental Fig S1 from STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers
Authors: Moreira Dayson , Adamus Tomasz , Zhao Xingli , Su Yu-Lin , Zhang Zhuoran , White Seok Voon , Swiderski Piotr , Lu Xin , DePinho Ronald A. , Pal Sumanta K. , Kortylewski Marcin
Published: April 2023

Serum stability of CpG-STAT3ASO
Video 3 from CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies
Authors: Bacac Marina , Colombetti Sara , Herter Sylvia , Sam Johannes , Perro Mario , Chen Stanford , Bianchi Roberta , Richard Marine , Schoenle Anne , Nicolini Valeria , Diggelmann Sarah , Limani Florian , Schlenker Ramona , Hüsser Tamara , Richter Wolfgang , Bray-French Katharine , Hinton Heather , Giusti Anna Maria , Freimoser-Grundschober Anne , Lariviere Laurent , Neumann Christiane , Klein Christian , Umaña Pablo
Published: April 2023

Supplemental Video 3. In vitro visualization of the dynamics of CD20-TCB (white) during interaction between CD8+ T-cells (green) and tumor cells (blue). The video focuses on an example of CD20-TCB-mediated CD8+ T-cell cytotoxicity of tumor cells. T-cells surround the tumor cells and create stable synapses where CD20-TCB is localized (white). Tumor cells are killed upon certain time of T-cell/tumor cell interaction as evidenced by the formation of tumor blebs.
Video 1 from CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies
Authors: Bacac Marina , Colombetti Sara , Herter Sylvia , Sam Johannes , Perro Mario , Chen Stanford , Bianchi Roberta , Richard Marine , Schoenle Anne , Nicolini Valeria , Diggelmann Sarah , Limani Florian , Schlenker Ramona , Hüsser Tamara , Richter Wolfgang , Bray-French Katharine , Hinton Heather , Giusti Anna Maria , Freimoser-Grundschober Anne , Lariviere Laurent , Neumann Christiane , Klein Christian , Umaña Pablo
Published: April 2023

Supplemental Video 1. In vitro visualization of the dynamics of untargeted TCB (white) during the interaction between CD8+ T-cells (green) and tumor cells (blue).
Figure S4 from Leukemia Inhibitory Factor Promotes Castration-resistant Prostate Cancer and Neuroendocrine Differentiation by Activated ZBTB46
Authors: Liu Yen-Nien , Niu Shaoxi , Chen Wei-Yu , Zhang Qingfu , Tao Yulei , Chen Wei-Hao , Jiang Kuo-Ching , Chen Xufeng , Shi Huaiyin , Liu Aijun , Li Jinhang , Li Yanjing , Lee Yi-Chao , Zhang Xu , Huang Jiaoti
Published: April 2023

Supplementary Figure S4
Figures S1-S6, Table S1-S2 from Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas
Authors: Dankner Matthew , Lajoie Mathieu , Moldoveanu Dan , Nguyen Tan-Trieu , Savage Paul , Rajkumar Shivshankari , Huang Xiu , Lvova Maria , Protopopov Alexei , Vuzman Dana , Hogg David , Park Morag , Guiot Marie-Christine , Petrecca Kevin , Mihalcioiu Catalin , Watson Ian R. , Siegel Peter M. , Rose April A.N.
Published: April 2023

FIGURE S1: LY3009120 is an effective inhibitor of BRAF class II mutant melanoma cells. FIGURE S2: Bioinformatic characterization of PDX models. FIGURE S3: Inhibitory effects of BRAF and MEK inhibitors in melanoma cells. FIGURE S4: Representative images from cell growth clonogenic assays. FIGURE S5: Encorafenib and binimetinib are an effective combination for class II BRAF mutant melanoma. FIGURE S6: Dual MAPK inhibition slows progression of class II BRAF mutant melanoma brain metastases.
Supplementary Figures from Comprehensive Profiling of DNA Repair Defects in Breast Cancer Identifies a Novel Class of Endocrine Therapy Resistance Drivers
Authors: Anurag Meenakshi , Punturi Nindo , Hoog Jeremy , Bainbridge Matthew N. , Ellis Matthew J. , Haricharan Svasti
Published: April 2023

Supplementary Figures with legends
Copy number calls from The Spatiotemporal Evolution of Lymph Node Spread in Early Breast Cancer
Authors: Barry Peter , Vatsiou Alexandra , Spiteri Inmaculada , Nichol Daniel , Cresswell George D. , Acar Ahmet , Trahearn Nicholas , Hrebien Sarah , Garcia-Murillas Isaac , Chkhaidze Kate , Ermini Luca , Huntingford Ian Said , Cottom Hannah , Zabaglo Lila , Koelble Konrad , Khalique Saira , Rusby Jennifer E. , Muscara Francesca , Dowsett Mitch , Maley Carlo C. , Natrajan Rachael , Yuan Yinyin , Schiavon Gaia , Turner Nicholas , Sottoriva Andrea
Published: April 2023

Copy number alterations calls
Appendix text from Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non–Small Cell Lung Cancer: A Phase Ib Study
Authors: Kim Edward S. , Kelly Karen , Paz-Ares Luis G. , Garrido Pilar , Jalal Shadia , Mahadevan Daruka , Gutierrez Martin , Provencio Mariano , Schaefer Eric , Shaheen Monte , Johnston Erica L. , Turner P. Kellie , Kambhampati Siva Rama Prasad , Beckmann Richard , Hossain Anwar , John William J. , Goldman Jonathan W.
Published: April 2023

First part of the appendix
Supplementary Table S1 from Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas)
Authors: Sanfilippo Roberta , Jones Robin L. , Blay Jean-Yves , Le Cesne Axel , Provenzano Salvatore , Antoniou Georgios , Mir Olivier , Fucà Giovanni , Fumagalli Elena , Bertulli Rossella , Stacchiotti Silvia , Brahmi Mehdi , Grosso Federica , Dufresne Armelle , Hindi Nadia , Sbaraglia Marta , Gronchi Alessandro , Collini Paola , Dei Tos Angelo P. , Casali Paolo G.
Published: April 2023

Specific agents used
Supplementary Table S5 from Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T-Cell Receptors in High-Risk MYCN-Not-Amplified Human Neuroblastoma
Authors: Wei Jun S. , Kuznetsov Igor B. , Zhang Shile , Song Young K. , Asgharzadeh Shahab , Sindiri Sivasish , Wen Xinyu , Patidar Rajesh , Najaraj Sushma , Walton Ashley , Auvil Jaime M. Guidry , Gerhard Daniela S. , Yuksel Aysen , Catchpoole Daniel , Hewitt Stephen M. , Sondel Paul M. , Seeger Robert , Maris John M. , Khan Javed
Published: April 2023

Supplementary Table S5
Supplementary Materials from Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T-Cell Receptors in High-Risk MYCN-Not-Amplified Human Neuroblastoma
Authors: Wei Jun S. , Kuznetsov Igor B. , Zhang Shile , Song Young K. , Asgharzadeh Shahab , Sindiri Sivasish , Wen Xinyu , Patidar Rajesh , Najaraj Sushma , Walton Ashley , Auvil Jaime M. Guidry , Gerhard Daniela S. , Yuksel Aysen , Catchpoole Daniel , Hewitt Stephen M. , Sondel Paul M. , Seeger Robert , Maris John M. , Khan Javed
Published: April 2023

Supplementary Materials
Supplementary Figure S1 from Activating Transcription Factor 4 Modulates TGFβ-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling
Authors: González-González Adrián , Muñoz-Muela Esperanza , Marchal Juan A. , Cara Francisca E. , Molina Maria P. , Cruz-Lozano Marina , Jiménez Gema , Verma Akanksha , Ramírez Alberto , Qian Wei , Chen Wen , Kozielski Anthony J. , Elemento Olivier , Martín-Salvago María D. , Luque Rafael J. , Rosa-Garrido Carmen , Landeira David , Quintana-Romero María , Rosato Roberto R. , García Maria A. , Ramirez-Tortosa Cesar L. , Kim Hanna , Rodriguez-Aguayo Cristian , Lopez-Berestein Gabriel , Sood Anil K. , Lorente Jose A. , Sánchez-Rovira Pedro , Chang Jenny C. , Granados-Principal Sergio
Published: April 2023

Supplementary Figure 1. Patient survival with high ATF4 expression in ER+ patients. ROC curve. Differential ATF4 expression induced by TGFβ1 and ERS. SBE motifs in ATF4 promoter and ChiP-Seq analysis.
Supplementary Figure S4 from High-Fat Diet-Induced Inflammation Accelerates Prostate Cancer Growth via IL6 Signaling
Authors: Hayashi Takuji , Fujita Kazutoshi , Nojima Satoshi , Hayashi Yujiro , Nakano Kosuke , Ishizuya Yu , Wang Cong , Yamamoto Yoshiyuki , Kinouchi Toshiro , Matsuzaki Kyosuke , Jingushi Kentaro , Kato Taigo , Kawashima Atsunari , Nagahara Akira , Ujike Takeshi , Uemura Motohide , Pena Maria Del Carmen Rodriguez , Gordetsky Jennifer B. , Morii Eiichi , Tsujikawa Kazutake , Netto George J. , Nonomura Norio
Published: April 2023

Positive controls of anti-mouse and anti-human antibodies for immunohistochemistry
Supplementary Table 1 from A Pilot Study of Liposomal Doxorubicin Combined with Bevacizumab followed by Bevacizumab Monotherapy in Patients with Advanced Kaposi Sarcoma
Authors: Ramaswami Ramya , Uldrick Thomas S. , Polizzotto Mark N. , Wyvill Kathleen M. , Goncalves Priscila , Widell Anaida , Lurain Kathryn , Steinberg Seth M. , Figg William Douglas , Tosato Giovanna , Whitby Denise , Yarchoan Robert
Published: April 2023

CD4 Count at baseline and after 6 cycles of combination therapy. . * For all patients, those in cohort 1 and 2, P values test the equality of the matched pair of CD4 counts from baseline to 6 cycles using Wilcoxon signed rank tests. All other P values denote comparison of the change in CD4 count from baseline to 6 cycles in responders as compared with non-responders using Wilcoxon rank sum tests.
Figure S4 from Genetic Polymorphisms Predisposing the Interleukin 6–Induced APOBEC3B-UNG Imbalance Increase HCC Risk via Promoting the Generation of APOBEC-Signature HBV Mutations
Authors: Liu Wenbin , Wu Jianfeng , Yang Fan , Ma Longteng , Ni Chong , Hou Xiaomei , Wang Ling , Xu Aijing , Song Jiahui , Deng Yang , Xian Linfeng , Li Zixiong , Wang Shuo , Chen Xi , Yin Jianhua , Han Xue , Li Chengzhong , Zhao Jun , Cao Guangwen
Published: April 2023

The effect of PMA on the expression of APOBEC3B and UNG as well as the activities of the transcriptional regulatory sequences with different rs2267401 and rs3890995 genotypes
Supplementary Table3 from Metastatic Breast Carcinoma–Associated Fibroblasts Have Enhanced Protumorigenic Properties Related to Increased IGF2 Expression
Authors: Gui Yirui , Aguilar-Mahecha Adriana , Krzemien Urszula , Hosein Abdel , Buchanan Marguerite , Lafleur Josiane , Pollak Michael , Ferrario Cristiano , Basik Mark
Published: April 2023

Supplementary Table3 shows Top 20 regulated genes in cluster 2 (predominant liver mCAFs).
Figure S1 from Metastatic Breast Carcinoma–Associated Fibroblasts Have Enhanced Protumorigenic Properties Related to Increased IGF2 Expression
Authors: Gui Yirui , Aguilar-Mahecha Adriana , Krzemien Urszula , Hosein Abdel , Buchanan Marguerite , Lafleur Josiane , Pollak Michael , Ferrario Cristiano , Basik Mark
Published: April 2023

Figure S1 shows the immunophenotype of CAFs
Supplementary table 3 from Predicted Prognosis of Patients with Pancreatic Cancer by Machine Learning
Authors: Yokoyama Seiya , Hamada Taiji , Higashi Michiyo , Matsuo Kei , Maemura Kosei , Kurahara Hiroshi , Horinouchi Michiko , Hiraki Tsubasa , Sugimoto Tomoyuki , Akahane Toshiaki , Yonezawa Suguru , Kornmann Marko , Batra Surinder K. , Hollingsworth Michael A. , Tanimoto Akihide
Published: April 2023

Univariate and multivariate analyses for overall survival (Cox proportional hazard model).
Supplementary table 1 from Predicted Prognosis of Patients with Pancreatic Cancer by Machine Learning
Authors: Yokoyama Seiya , Hamada Taiji , Higashi Michiyo , Matsuo Kei , Maemura Kosei , Kurahara Hiroshi , Horinouchi Michiko , Hiraki Tsubasa , Sugimoto Tomoyuki , Akahane Toshiaki , Yonezawa Suguru , Kornmann Marko , Batra Surinder K. , Hollingsworth Michael A. , Tanimoto Akihide
Published: April 2023

Comparison of SVM predict ability among these kernels in LOOCV
Supplementary Table S2 from Germline BRCA-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity
Authors: de Jonge Marthe M. , Ritterhouse Lauren L. , de Kroon Cornelis D. , Vreeswijk Maaike P.G. , Segal Jeremy P. , Puranik Rutika , Hollema Harry , Rookus Matti A. , van Asperen Christi J. , van Leeuwen Flora E. , Smit Vincent T.H.B.M. , Howitt Brooke E. , Bosse Tjalling
Published: April 2023

Germline BRCA1/2 Mutations and Variant Allele Frequencies detected in the FFPE-isolated tumor DNA
Supplementary Fig. S5 from Germline BRCA-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity
Authors: de Jonge Marthe M. , Ritterhouse Lauren L. , de Kroon Cornelis D. , Vreeswijk Maaike P.G. , Segal Jeremy P. , Puranik Rutika , Hollema Harry , Rookus Matti A. , van Asperen Christi J. , van Leeuwen Flora E. , Smit Vincent T.H.B.M. , Howitt Brooke E. , Bosse Tjalling
Published: April 2023

Class 4/5 mutations and Tumor Mutational Burden stratified by loss of heterozygosity status.
Supplementary Fig. S3 from Germline BRCA-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity
Authors: de Jonge Marthe M. , Ritterhouse Lauren L. , de Kroon Cornelis D. , Vreeswijk Maaike P.G. , Segal Jeremy P. , Puranik Rutika , Hollema Harry , Rookus Matti A. , van Asperen Christi J. , van Leeuwen Flora E. , Smit Vincent T.H.B.M. , Howitt Brooke E. , Bosse Tjalling
Published: April 2023

Examples of morphological characteristics associated with gBRCA/LOHpos ECs.
Supplementary Fig. S1 from Germline BRCA-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity
Authors: de Jonge Marthe M. , Ritterhouse Lauren L. , de Kroon Cornelis D. , Vreeswijk Maaike P.G. , Segal Jeremy P. , Puranik Rutika , Hollema Harry , Rookus Matti A. , van Asperen Christi J. , van Leeuwen Flora E. , Smit Vincent T.H.B.M. , Howitt Brooke E. , Bosse Tjalling
Published: April 2023

Position and frequency of gBRCA1/2 mutations across the coding DNA sequence.
Supplementary Figure 1 from A Novel HER3-Targeting Antibody–Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization
Authors: Hashimoto Yuuri , Koyama Kumiko , Kamai Yasuki , Hirotani Kenji , Ogitani Yusuke , Zembutsu Akiko , Abe Manabu , Kaneda Yuki , Maeda Naoyuki , Shiose Yoshinobu , Iguchi Takuma , Ishizaka Tomomichi , Karibe Tsuyoshi , Hayakawa Ichiro , Morita Koji , Nakada Takashi , Nomura Taisei , Wakita Kenichi , Kagari Takashi , Abe Yuki , Murakami Masato , Ueno Suguru , Agatsuma Toshinori
Published: April 2023

Cell surface expression of HER3 and HER2 on human cancer cell lines
Supplementary Data from Impact of a Pre-Operative Exercise Intervention on Breast Cancer Proliferation and Gene Expression: Results from the Pre-Operative Health and Body (PreHAB) Study
Authors: Ligibel Jennifer A. , Dillon Deborah , Giobbie-Hurder Anita , McTiernan Anne , Frank Elizabeth , Cornwell MacIntosh , Pun Matthew , Campbell Nancy , Dowling Ryan J.O. , Chang Martin C. , Tolaney Sara , Chagpar Anees B. , Yung Rachel L. , Freedman Rachel A. , Dominici Laura S. , Golshan Mehra , Rhei Esther , Taneja Krishan , Huang Ying , Brown Myles , Winer Eric P. , Jeselsohn Rinath , Irwin Melinda L.
Published: April 2023

Supplemental Figure 1: Study Schema Supplemental Table 1: Tissue Insulin Receptor Staining
Supplementary Figure S4 from Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer
Authors: Gray Jhanelle E. , Saltos Andreas , Tanvetyanon Tawee , Haura Eric B. , Creelan Ben , Antonia Scott J. , Shafique Michael , Zheng Hong , Dai Wenjie , Saller James J. , Chen Zhihua , Tchekmedyian Nishan , Goas Kristen , Thapa Ram , Boyle Theresa A. , Chen Dung-Tsa , Beg Amer A.
Published: April 2023

Hematoxylin and eosin (HE) and immunohistochemistry (IHC) stains to detect CD8+ and CD33+ cells in patients who received clinical benefit.
Legends for Supplementary Figures from IL23-Producing Human Lung Cancer Cells Promote Tumor Growth via Conversion of Innate Lymphoid Cell 1 (ILC1) into ILC3
Authors: Koh Jaemoon , Kim Hye Young , Lee Youngha , Park In Kyu , Kang Chang Hyun , Kim Young Tae , Kim Ji-Eun , Choi Murim , Lee Won-Woo , Jeon Yoon Kyung , Chung Doo Hyun
Published: April 2023

Legends for Supplementary Figures
Supplementary Data from Phosphoproteomic and Kinomic Signature of Clinically Aggressive Grade I (1.5) Meningiomas Reveals RB1 Signaling as a Novel Mediator and Biomarker
Authors: Parada Carolina A. , Osbun Joshua W. , Busald Tina , Karasozen Yigit , Kaur Sumanpreet , Shi Min , Barber Jason , Adidharma Widya , Cimino Patrick J. , Pan Catherine , Gonzalez-Cuyar Luis F. , Rostomily Robert , Born Donald E. , Zhang Jing , Ferreira Manuel
Published: April 2023

Figure S2, S3, S4, S6, S7, S8, S9 and tables
Supplementary Table S1 from BAP1 Loss Is Associated with DNA Methylomic Repatterning in Highly Aggressive Class 2 Uveal Melanomas
Authors: Field Matthew G. , Kuznetsov Jeffim N. , Bussies Parker L. , Cai Louie Z. , Alawa Karam A. , Decatur Christina L. , Kurtenbach Stefan , Harbour J. William
Published: April 2023

Methylation validation probe targets with forward and reverse primers and the optimized annealing temperature
Table S3 from Comprehensive Next-Generation Sequencing Unambiguously Distinguishes Separate Primary Lung Carcinomas From Intrapulmonary Metastases: Comparison with Standard Histopathologic Approach
Authors: Chang Jason C. , Alex Deepu , Bott Matthew , Tan Kay See , Seshan Venkatraman , Golden Andrew , Sauter Jennifer L. , Buonocore Darren J. , Vanderbilt Chad M. , Gupta Sounak , Desmeules Patrice , Bodd Francis M. , Riely Gregory J. , Rusch Valerie W. , Jones David R. , Arcila Maria E. , Travis William D. , Ladanyi Marc , Rekhtman Natasha
Published: April 2023

Supplemental Table 3
Table S2 from Comprehensive Next-Generation Sequencing Unambiguously Distinguishes Separate Primary Lung Carcinomas From Intrapulmonary Metastases: Comparison with Standard Histopathologic Approach
Authors: Chang Jason C. , Alex Deepu , Bott Matthew , Tan Kay See , Seshan Venkatraman , Golden Andrew , Sauter Jennifer L. , Buonocore Darren J. , Vanderbilt Chad M. , Gupta Sounak , Desmeules Patrice , Bodd Francis M. , Riely Gregory J. , Rusch Valerie W. , Jones David R. , Arcila Maria E. , Travis William D. , Ladanyi Marc , Rekhtman Natasha
Published: April 2023

Supplemental Table 2
Table S1 from Comprehensive Next-Generation Sequencing Unambiguously Distinguishes Separate Primary Lung Carcinomas From Intrapulmonary Metastases: Comparison with Standard Histopathologic Approach
Authors: Chang Jason C. , Alex Deepu , Bott Matthew , Tan Kay See , Seshan Venkatraman , Golden Andrew , Sauter Jennifer L. , Buonocore Darren J. , Vanderbilt Chad M. , Gupta Sounak , Desmeules Patrice , Bodd Francis M. , Riely Gregory J. , Rusch Valerie W. , Jones David R. , Arcila Maria E. , Travis William D. , Ladanyi Marc , Rekhtman Natasha
Published: April 2023

Supplemental Table 1
Supplemental Methods from Comprehensive Next-Generation Sequencing Unambiguously Distinguishes Separate Primary Lung Carcinomas From Intrapulmonary Metastases: Comparison with Standard Histopathologic Approach
Authors: Chang Jason C. , Alex Deepu , Bott Matthew , Tan Kay See , Seshan Venkatraman , Golden Andrew , Sauter Jennifer L. , Buonocore Darren J. , Vanderbilt Chad M. , Gupta Sounak , Desmeules Patrice , Bodd Francis M. , Riely Gregory J. , Rusch Valerie W. , Jones David R. , Arcila Maria E. , Travis William D. , Ladanyi Marc , Rekhtman Natasha
Published: April 2023

Supplemental Methods
Figure S1 from The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition
Authors: Parmar Kalindi , Kochupurakkal Bose S. , Lazaro Jean-Bernard , Wang Zhigang C. , Palakurthi Sangeetha , Kirschmeier Paul T. , Yang Chunyu , Sambel Larissa A. , Färkkilä Anniina , Reznichenko Elizaveta , Reavis Hunter D. , Dunn Connor E. , Zou Lee , Do Khanh T. , Konstantinopoulos Panagiotis A. , Matulonis Ursula A. , Liu Joyce F. , D'Andrea Alan D. , Shapiro Geoffrey I.
Published: April 2023

Prexasertib exhibits monotherapy activity in olaparib-resistant HGSOC PDX models
Supplementary Data from Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study
Authors: Colomban Olivier , Tod Michel , Leary Alexandra , Ray-Coquard Isabelle , Lortholary Alain , Hardy-Bessard Anne Claire , Pfisterer Jacobus , Du Bois Andreas , Kurzeder Christian , Burges Alexander , Péron Julien , Freyer Gilles , You Benoit
Published: April 2023

Supplementary Methods. Basic Population Modeling. /// Supplementary Table S1. Characteristics of the patients included in the landmark survival analysis. Supplementary Table S2. Typical parameter estimates from the final semi-mechanistic model in the learning set AGO-OVAR 9. Supplementary Table S3. Predictive value of KELIM terciles and other prognostic factors regarding progression-free survival (PFS) and overall survival (OS) in univariate and multivariate models in every trial considered separately. Supplementary Table S4. Covariates associated with progression-free survival (PFS-months) in the 3 datasets. Supplementary Table S5. Impact of KELIM terciles on PFS (progression-free survival) and OS (overall survival) adjusted on risk classes defined by Oza et al. in the ICON 7 trial. Supplementary Table S6. Univariate Weibull accelerated failure time model regarding overall survival (OS) on the pooled datasets. /// Supplementary Figure S1. Semi-mechanistic model. AMT is the amount of drug administered. C1 and C2 are the drug concentration in compartment 1 and 2 (Arbitrary Units). Supplementary Figure S2. Goodness-of-fit plot for the AGO-OVAR 9 learning set. Predicted versus observed concentrations are shown for (left) the population and for (right) individuals. Black line: identity line. Supplementary Figure S3. Visual predictive checks for the 3 datasets. Supplementary Figure S4. Predictive value of KELIM and other prognostic factors regarding progression free survival (PFS, left panel) and overall survival (OS, right panel) assessed using C-index. Supplementary Figure S5. Linear regression between overall survival hazard ratios and KELIM ratios in the 3 phase III trials. Supplementary Figure S6. Outcomes of overall survival analyses with KELIM adjusted for the treatment arms (ARM) for the three datasets (the learning set AGO-OVAR 9; the two validation sets AGO-OVAR7 and ICON-7).
Supplemental Figure 4 from B7-H3 Expression in Merkel Cell Carcinoma–Associated Endothelial Cells Correlates with Locally Aggressive Primary Tumor Features and Increased Vascular Density
Authors: Aung Phyu P. , Parra Edwin Roger , Barua Souptik , Sui Dawen , Ning Jing , Mino Barbara , Ledesma Debora Alejandra , Curry Jonathan L. , Nagarajan Priyadharsini , Torres-Cabala Carlos A. , Efstathiou Eleni , Hoang Anh G. , Wong Michael K. , Wargo Jennifer A. , Lazar Alexander J. , Rao Arvind , Prieto Victor G. , Wistuba Ignacio , Tetzlaff Michael T.
Published: April 2023

Supplemental Figure 4. Correlation between B7-H3/CD31 G-function co-localization index and vascular density. Plots showing the correlation B7-H3/CD31 G-function co-localization index plotted against vascular density for the whole cohort of primary MCC (vascular density tabulated as the average of the regions of interest in each of the 52 tumors).
Supplementary Figures S1-S5 from BIRC3 Expression Predicts CLL Progression and Defines Treatment Sensitivity via Enhanced NF-κB Nuclear Translocation
Authors: Asslaber Daniela , Wacht Nathalie , Leisch Michael , Qi Yuan , Maeding Nicole , Hufnagl Clemens , Jansko Bettina , Zaborsky Nadja , Villunger Andreas , Hartmann Tanja N. , Greil Richard , Egle Alexander
Published: April 2023

Supplementary Figures S1-S5
Supplementary Data from High-Plex Predictive Marker Discovery for Melanoma Immunotherapy–Treated Patients Using Digital Spatial Profiling
Authors: Toki Maria I. , Merritt Christopher R. , Wong Pok Fai , Smithy James W. , Kluger Harriet M. , Syrigos Konstantinos N. , Ong Giang T. , Warren Sarah E. , Beechem Joseph M. , Rimm David L.
Published: April 2023

Table S1: Immune marker panels used in NanoString DSP. CAB# is custom antibody ID, which uniquely identifies this reagent. Table S2: Clinicopathological characteristics of EGFR TKI treated NSCLC patients in Yale cohort A. Table S3: Clinicopathological characteristics of NSCLC patients in Yale cohort B. Table S4: Clinicopathological characteristics of ICIs treated melanoma patients in Yale cohort C. Table S5: Multivariate analysis of the predictive markers for PFS in Yale melanoma ICIs treated cohort C. Table S6: Multivariate analysis of the predictive markers for OS in Yale melanoma ICIs treated cohort C. Figure S1: Representative images of NanoString DSP and AQUA compartment selection in NSCLC. The epithelial compartment was defined by cytokeratin positivity (green) which allowed the measurement of targets by both assays in the same compartment. Stroma was defined by cytokeratin negative DNA positive regions (purple). Figure S2: NanoString DSP reproducibility across different cores in ITx melanoma cohort C. (A) CD8 reproducibility across 2 cores (B) CD68 reproducibility across 2 cores Figure S3: NanoString DSP sequential compartment assignment. CD8 counts by NanoString DSP in tumor, CD68+ and CD45+ compartment. Compartment definition accuracy is affected by the order of barcode collection from each compartment. In overlapping compartments, measurement of a marker can be assigned to only one compartment.
Supplemental Figure 2 from B7-H3 Expression in Merkel Cell Carcinoma–Associated Endothelial Cells Correlates with Locally Aggressive Primary Tumor Features and Increased Vascular Density
Authors: Aung Phyu P. , Parra Edwin Roger , Barua Souptik , Sui Dawen , Ning Jing , Mino Barbara , Ledesma Debora Alejandra , Curry Jonathan L. , Nagarajan Priyadharsini , Torres-Cabala Carlos A. , Efstathiou Eleni , Hoang Anh G. , Wong Michael K. , Wargo Jennifer A. , Lazar Alexander J. , Rao Arvind , Prieto Victor G. , Wistuba Ignacio , Tetzlaff Michael T.
Published: April 2023

Supplemental Figure 2. Correlation between B7-H3/CD31 G-function co-localization index in MCPyV-positive MCCs. Plots showing the correlation B7-H3/CD31 G-function co-localization index for each primary MCPyV-positive MCC plotted against tumor size (A), depth of invasion (B), invasion beyond skin (C) and metastasis beyond SLN (D). G-function calculated according to a 1 pixel (1.57 ï�­m) radius.
Supplementary Tables 1-11 from HDAC Inhibition Enhances the In Vivo Efficacy of MEK Inhibitor Therapy in Uveal Melanoma
Authors: Faião-Flores Fernanda , Emmons Michael F. , Durante Michael A. , Kinose Fumi , Saha Biswarup , Fang Bin , Koomen John M. , Chellappan Srikumar P. , Maria-Engler Silvya Stuchi , Rix Uwe , Licht Jonathan D. , Harbour J. William , Smalley Keiran S.M.
Published: April 2023

Supplementary Table S1- Antibodies used for protein expression in western blotting experiments Supplementary Table S2 - Assays used for gene expression in RT-qPCR experiments Supplementary Table S3 - Antibodies used for protein expression in immunofluorescence experiments Supplementary Table S4 - Inhibitory concentration 50% (IC50) of MEKi after 72h in uveal melanoma cell lines (nM) Supplementary Table S5 - Members of the GSEA GO_REGULATION_OF_PHOSPHATIDYLINOSITOL_3_KINASE_SIGNALING family Supplementary Table S6 - Members of the GSEA GO_TRANSMEMBRANE_RECEPTOR_PROTEIN_KINASE_ACTIVITY family Supplementary Table S7 - Members of the GSEA GO_TRANSMEMBRANE_RECEPTOR_PROTEIN_TYROSINE_KINASE_ACTIVITY family Supplementary Table S8 - Members of the GSEA HIPPO_TARGETS family Supplementary Table S9 - Members of the GSEA REACTOME_GPCR_LIGAND_BINDING Family Supplementary Table S10 - Compounds used in the drug screening Supplementary Table S11 - Members of the GSEA HALLMARK_PI3K_AKT_MTOR_SIGNALING
Supplementary Figures 1-12 from HDAC Inhibition Enhances the In Vivo Efficacy of MEK Inhibitor Therapy in Uveal Melanoma
Authors: Faião-Flores Fernanda , Emmons Michael F. , Durante Michael A. , Kinose Fumi , Saha Biswarup , Fang Bin , Koomen John M. , Chellappan Srikumar P. , Maria-Engler Silvya Stuchi , Rix Uwe , Licht Jonathan D. , Harbour J. William , Smalley Keiran S.M.
Published: April 2023

Supplemental Figure 1: Gene ontology network analysis of uveal melanoma cells following MEKi treatment (24h) and ABPP. Supplemental Figure 2: ET-3 increases nuclear accumulation of YAP in 92.1, Mel270, MP41 and OMM1 cells. Supplemental Figure 3: ET-1 does not induce YAP reporter activity in 92.1 or Mel270 cells. Supplemental Figure 4: HDAC inhibitors increase the cytotoxic effects of MEK inhibition. Supplemental Figure 5: MEK inhibition leads to an increase in global protein acetylation in uveal melanoma cells. Supplemental Figure 6: MEKi, HDACi and the MEKi-HDACi combination do not affect the survival of primary uveal melanocytes. Supplemental Figure 7: HDACi suppresses MEKi-induced release of ET-3 from uveal melanoma cells. Supplemental Figure 8: Negative modulation of PI3K-AKT pathway by combinatory treatment with MEKi+HDACi. Supplemental Figure 9: The MEK-HDACi combination delivers durable responses in the 92.1 uveal melanoma xenograft model. Supplemental Figure 10: Macroscopic findings of liver tumor formation after inoculation of MP41 by tail vein injection. Supplemental Figure 11: Uncropped blots Supplemental Figure 12: Flow cytometry plots
Supplementary Data from BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma
Authors: Boyle Eileen M. , Ashby Cody , Tytarenko Ruslana G. , Deshpande Shayu , Wang Hongwei , Wang Yan , Rosenthal Adam , Sawyer Jeffrey , Tian Erming , Flynt Erin , Hoering Antje , Johnson Sarah K. , Rutherford Michael W. , Wardell Christopher P. , Bauer Michael A. , Dumontet Charles , Facon Thierry , Thanendrarajan Sharmilan , Schinke Carolina D. , Zangari Maurizio , van Rhee Frits , Barlogie Bart , Cairns David , Jackson Graham , Thakurta Anjan , Davies Faith E. , Morgan Gareth J. , Walker Brian A.
Published: April 2023

Clean and unmarked supplemental data
Figure S6 from A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2)
Authors: Mazzu Ying Z. , Armenia Joshua , Chakraborty Goutam , Yoshikawa Yuki , Coggins Si'Ana A. , Nandakumar Subhiksha , Gerke Travis A. , Pomerantz Mark M. , Qiu Xintao , Zhao Huiyong , Atiq Mohammad , Khan Nabeela , Komura Kazumasa , Lee Gwo-Shu Mary , Fine Samson W. , Bell Connor , O'Connor Edward , Long Henry W. , Freedman Matthew L. , Kim Baek , Kantoff Philip W.
Published: April 2023

Figure S6
Table S1 from Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer
Authors: Liu Li , Bai Xue , Wang Jian , Tang Xin-Ran , Wu De-Hua , Du Sha-Sha , Du Xiu-Ju , Zhang Yao-Wei , Zhu Hong-Bo , Fang Yuan , Guo Ze-Qin , Zeng Qin , Guo Xue-Jun , Liu Zhu , Dong Zhong-Yi
Published: April 2023

Demographic and clinicopathologic characteristics of three cohorts treated with immune checkpoint inhibitors.
Figure S6 from Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer
Authors: Liu Li , Bai Xue , Wang Jian , Tang Xin-Ran , Wu De-Hua , Du Sha-Sha , Du Xiu-Ju , Zhang Yao-Wei , Zhu Hong-Bo , Fang Yuan , Guo Ze-Qin , Zeng Qin , Guo Xue-Jun , Liu Zhu , Dong Zhong-Yi
Published: April 2023

Relationship between HRD mutation and TMB in (A) MSK NSCLC ICI cohort and (B) Dana-Farber ICI cohort. For each cohort, a plot is shown containing the HRD mutation status versus the tumor mutation burden. The P value is shown.
Figure S3 from A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2)
Authors: Mazzu Ying Z. , Armenia Joshua , Chakraborty Goutam , Yoshikawa Yuki , Coggins Si'Ana A. , Nandakumar Subhiksha , Gerke Travis A. , Pomerantz Mark M. , Qiu Xintao , Zhao Huiyong , Atiq Mohammad , Khan Nabeela , Komura Kazumasa , Lee Gwo-Shu Mary , Fine Samson W. , Bell Connor , O'Connor Edward , Long Henry W. , Freedman Matthew L. , Kim Baek , Kantoff Philip W.
Published: April 2023

Figure S3
Figure S4 from Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer
Authors: Liu Li , Bai Xue , Wang Jian , Tang Xin-Ran , Wu De-Hua , Du Sha-Sha , Du Xiu-Ju , Zhang Yao-Wei , Zhu Hong-Bo , Fang Yuan , Guo Ze-Qin , Zeng Qin , Guo Xue-Jun , Liu Zhu , Dong Zhong-Yi
Published: April 2023

Sensitivity analysis of overall survival (OS) or progression-free survival (PFS) in three cohorts treated with immune checkpoint inhibitor (ICI) by altering cut-point (median, tertile, quartile) of TMB and CNA. (A) Univariate analysis of treatment survival in three ICI treated cohorts with different cut-points (median, tertile, quartile) of TMB and CNA. (B-D) Multivariate analysis of treatment survival in three ICI treated cohorts with the inclusion of alternate cut-points of CNA and TMB, and illustrated in three groups stratified by the cut-points of CNA (B: {greater than or equal to}median vs
Figure S2 from EZH2 Is Overexpressed in BRCA1-like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy
Authors: Puppe Julian , Opdam Mark , Schouten Philip C. , Jóźwiak Katarzyna , Lips Esther , Severson Tesa , van de Ven Marieke , Brambillasca Chiara , Bouwman Peter , van Tellingen Olaf , Bernards René , Wesseling Jelle , Eichler Christian , Thangarajah Fabinshy , Malter Wolfram , Pandey Gaurav Kumar , Ozretić Luka , Caldas Carlos , van Lohuizen Maarten , Hauptmann Michael , Rhiem Kerstin , Hahnen Eric , Reinhardt H. Christian , Büttner Reinhard , Mallmann Peter , Schömig-Markiefka Birgid , Schmutzler Rita , Linn Sabine , Jonkers Jos
Published: April 2023

Predictive value of EZH2-expression in non-BRCA1-like breast cancer patients treated with conventional (CONV) or high dose (HD) platinum-based chemotherapy (Set IV N4+, HER2-negative) divided by ER status
Table S3 from A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors
Authors: Aloia Andrea , Müllhaupt Daniela , Chabbert Christophe D. , Eberhart Tanja , Flückiger-Mangual Stefanie , Vukolic Ana , Eichhoff Ossia , Irmisch Anja , Alexander Leila T. , Scibona Ernesto , Frederick Dennie T. , Miao Benchun , Tian Tian , Cheng Chaoran , Kwong Lawrence N. , Wei Zhi , Sullivan Ryan J. , Boland Genevieve M. , Herlyn Meenhard , Flaherty Keith T. , Zamboni Nicola , Dummer Reinhard , Zhang Gao , Levesque Mitchell P. , Krek Wilhelm , Kovacs Werner J.
Published: April 2023

Table S3, related to Figure 1 and Figure S1
Table S1 from A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors
Authors: Aloia Andrea , Müllhaupt Daniela , Chabbert Christophe D. , Eberhart Tanja , Flückiger-Mangual Stefanie , Vukolic Ana , Eichhoff Ossia , Irmisch Anja , Alexander Leila T. , Scibona Ernesto , Frederick Dennie T. , Miao Benchun , Tian Tian , Cheng Chaoran , Kwong Lawrence N. , Wei Zhi , Sullivan Ryan J. , Boland Genevieve M. , Herlyn Meenhard , Flaherty Keith T. , Zamboni Nicola , Dummer Reinhard , Zhang Gao , Levesque Mitchell P. , Krek Wilhelm , Kovacs Werner J.
Published: April 2023

Table S1 contains antibody details of the LEGENDScreen Human PE Kit from Biolegend
Supplementary Data from A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors
Authors: Aloia Andrea , Müllhaupt Daniela , Chabbert Christophe D. , Eberhart Tanja , Flückiger-Mangual Stefanie , Vukolic Ana , Eichhoff Ossia , Irmisch Anja , Alexander Leila T. , Scibona Ernesto , Frederick Dennie T. , Miao Benchun , Tian Tian , Cheng Chaoran , Kwong Lawrence N. , Wei Zhi , Sullivan Ryan J. , Boland Genevieve M. , Herlyn Meenhard , Flaherty Keith T. , Zamboni Nicola , Dummer Reinhard , Zhang Gao , Levesque Mitchell P. , Krek Wilhelm , Kovacs Werner J.
Published: April 2023

Contains Supplementary materials and methods, Supplementary Figures S1-S9, Table S2, Table S4, Supplemental References Figure S1, related to Figure 1. Cell surface marker screening of A375P cells treated with vehicle (DMSO) or PLX. Figure S2, related to Figure 1. CD36 is a biomarker of the early stage of MAPK inhibition in melanoma. Figure S3, related to Figure 1. MAPK inhibition induces and maintains the CD36+ population in melanoma cells Figure S4, related to Figure 2. MAPKi induce the expression of genes involved in lipid catabolism in BRAFV600E melanomas. Figure S5, related to Figure 3. MAPK inhibition decreased the glycolytic flux in BRAF-mutated melanoma cells. Figure S6, related to Figure 4. Phenotypic and metabolic characterization of CD36 WT, CD36 KO, CD36+ and CD36- A375P cells. Figure S7, related to Figure 5. PPARα does not regulate CD36 expression. Figure S8, related to Figure 6. Role of glycolysis and FAO inhibitors in proliferation and resistance to MAPKi Figure S9, related to Figure 6. Effects of MAPK, glycolysis and FAO inhibition on mouse and tumor weight. Table S2, related to Figure 1, Figure 3, Figure 6, Figure S3 and Figure S6. Primer list. Table S4, related to Figure 1 and Figure S2. Cell lines, their mutational status and their responsiveness to MAPK inhibitors.
Table S1 from Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)
Authors: Le Dung T. , Picozzi Vincent J. , Ko Andrew H. , Wainberg Zev A. , Kindler Hedy , Wang-Gillam Andrea , Oberstein Paul , Morse Michael A. , Zeh Herbert J. , Weekes Colin , Reid Tony , Borazanci Erkut , Crocenzi Todd , LoConte Noelle K. , Musher Benjamin , Laheru Dan , Murphy Aimee , Whiting Chan , Nair Nitya , Enstrom Amanda , Ferber Sandy , Brockstedt Dirk G. , Jaffee Elizabeth M.
Published: April 2023

Baseline disease characteristics by treatment arm
Figure S7 from Evolutionary Routes in Metastatic Uveal Melanomas Depend on MBD4 Alterations
Authors: Rodrigues Manuel , Mobuchon Lenha , Houy Alexandre , Alsafadi Samar , Baulande Sylvain , Mariani Odette , Marande Benjamin , Ait Rais Khadija , Van der Kooij Monique K. , Kapiteijn Ellen , Gassama Sieta , Gardrat Sophie , Barnhill Raymond L. , Servois Vincent , Dendale Rémi , Putterman Marc , Tick Sarah , Piperno-Neumann Sophie , Cassoux Nathalie , Pierron Gaëlle , Waterfall Joshua J. , Roman-Roman Sergio , Mariani Pascale , Stern Marc-Henri
Published: April 2023

Supplementary figure 7 - Minigene assay of BAP1 intronic insert splicing.
Figure S1 from Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)
Authors: Le Dung T. , Picozzi Vincent J. , Ko Andrew H. , Wainberg Zev A. , Kindler Hedy , Wang-Gillam Andrea , Oberstein Paul , Morse Michael A. , Zeh Herbert J. , Weekes Colin , Reid Tony , Borazanci Erkut , Crocenzi Todd , LoConte Noelle K. , Musher Benjamin , Laheru Dan , Murphy Aimee , Whiting Chan , Nair Nitya , Enstrom Amanda , Ferber Sandy , Brockstedt Dirk G. , Jaffee Elizabeth M.
Published: April 2023

Progression-free survival by treatment arm: Primary Cohort